10-Q: Genprex Faces Delisting, Going Concern Amid Cash Crunch

Genprex, Inc. reports reduced net losses but faces significant financial challenges including a going concern warning, Nasdaq delisting threat, and limited cash runway through August 2025.

Summary

• Net loss for the three months ended June 30, 2025, decreased to $4.67 million from $6.50 million in the prior year period, a 28% improvement.
• Net loss for the six months ended June 30, 2025, decreased to $8.64 million from $12.46 million in the prior year period, a 31% improvement.
• Research and development (R&D) expense increased by 50% to $2.50 million for the three months ended June 30, 2025, primarily due to a one-time refund in the prior year and differences in clinical trial enrollment.
• General and administrative (G&A) expense decreased by 55% to $2.18 million for the three months ended June 30, 2025, due to expense reduction strategies, including reduced travel, professional services, and headcount.
• Cash and cash equivalents stood at $1.35 million as of June 30, 2025, down from $1.60 million at December 31, 2024.
• The company has utilized its full 5,561,445 share capacity under the Nasdaq Exchange Cap for its 2025 ELOC Facility and has no remaining capacity under its 2023 ATM Facility.
• Genprex received a letter from Nasdaq on August 12, 2025, indicating a delisting determination due to non-compliance with the $1.00 minimum bid price requirement and ineligibility for a further extension.
• Management has identified material weaknesses in internal controls over financial reporting related to lack of segregation of duties and insufficient depth of in-house accounting personnel for complex transactions.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including a going concern warning, imminent Nasdaq delisting, and an extremely short cash runway. While there is some clinical progress and new licensing, these are heavily overshadowed by the critical financial instability and operational challenges, leading to a very negative outlook.

Positives

• Net loss significantly decreased by 28% for the three months and 31% for the six months ended June 30, 2025, compared to the prior year periods.
• General and administrative expenses were substantially reduced by 55% for the three months and 52% for the six months ended June 30, 2025, reflecting successful expense reduction strategies.
• Acclaim-1 (NSCLC) Phase 2a expansion portion is actively enrolling and treating patients, with a recommended Phase 2 dose (RP2D) of 0.12 mg/kg established.
• Acclaim-1 has received FDA Fast Track Designation, potentially accelerating its development and review process.
• Acclaim-3 (ES-SCLC) Phase 2 expansion portion is actively enrolling and treating patients, with an RP2D of 0.12 mg/kg established, and has received both FDA Fast Track and Orphan Drug Designations.
• Preclinical data for GPX-002 (diabetes gene therapy) in non-human primate models of Type 1 diabetes showed decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance.
• New exclusive license agreements were secured with NYU for mesothelioma treatment and UTHealth Houston for glioblastoma treatment, expanding the oncology pipeline.
• A new sponsored research agreement was entered with the University of Pittsburgh in May 2025 to further study Type 1 and Type 2 diabetes in animal models, incorporating recent technologies.

Negatives

• The company has sustained substantial losses from operations since inception and has no current source of revenue, raising substantial doubt about its ability to continue as a going concern.
• Current cash and cash equivalents of $1.35 million are estimated to be sufficient to fund operations only through the end of August 2025, indicating an extremely short cash runway.
• Genprex received a delisting determination letter from Nasdaq on August 12, 2025, due to non-compliance with the $1.00 minimum bid price requirement and ineligibility for a further extension.
• Material weaknesses in internal controls over financial reporting were identified, specifically a lack of segregation of duties and insufficient depth of in-house accounting personnel for complex transactions.
• The Acclaim-2 clinical trial was ceased in August 2024 due to enrollment challenges, delays, and resource prioritization, indicating a setback in that program.
• Research and development expenses increased by 50% for the three months ended June 30, 2025, compared to the prior year, contributing to continued cash burn.
• The company has fully utilized its available capacity under both the 2023 ATM Facility and the Nasdaq Exchange Cap for the 2025 ELOC Facility, requiring stockholder approval for further capital raises through the ELOC.

Risks

• Inability to raise additional future financing, leading to a lack of financial resources to support preclinical and clinical development programs and business growth.
• Failure to continue as a going concern, which could result in the inability to realize assets and liquidate liabilities in the normal course of business.
• Failure to regain and maintain compliance with Nasdaq's continued listing requirements, potentially leading to delisting and a negative impact on stock price and access to capital markets.
• Uncertainty of developing marketable products and obtaining regulatory approvals for product candidates.
• Dependence on third-party suppliers or manufacturers to supply or manufacture key ingredients and products, with potential for delays or inability to meet clinical trial needs.
• Delays in regulatory review and approval of current and future product candidates.
• Involvement in patent, trademark, and other intellectual property litigation, which could be expensive and divert management's attention.
• Lack of market acceptance for products, even if approved.
• Changes in third-party reimbursement policies, which could adversely affect potential future sales of approved products.
• Material weaknesses in internal controls over financial reporting, specifically a lack of segregation of duties and insufficient depth of in-house accounting personnel, which could affect financial reporting reliability.

Future Outlook

Genprex expects to continue incurring significant expenditures for clinical trials and commercial development. The company anticipates needing to raise additional capital to fund future operations, including advancing Acclaim-1 and Acclaim-3 clinical trials and preclinical work for diabetes and other oncology candidates. Enrollment for interim analysis in Acclaim-1 Phase 2a is expected by Q1 2026, with interim analysis in H1 2026. Enrollment for interim analysis in Acclaim-3 Phase 2 is also expected by Q1 2026. The company plans to seek further regulatory guidance from the FDA on IND-enabling studies for its diabetes program in the second half of 2025.

Management Comments

• We believe that our current cash and cash equivalents will be sufficient to fund expenditure requirements for our necessary operations and expected clinical trial activities through the end of August 2025.
• We recognize that we must obtain additional capital resources to successfully commercialize our product candidates.
• As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company's ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company's ability to continue as a going concern.
• We intend to timely request a hearing before the Nasdaq Hearings Panel, at which hearing we will request an extension within which to evidence compliance with all applicable requirements for continued listing on Nasdaq, including compliance with the Bid Price Requirement.
• We intend to continue to take definitive steps in an effort to evidence compliance with the Bid Price Requirement, including by effecting a reverse stock split.

Industry Context

Genprex operates in the highly competitive and capital-intensive gene therapy sector, focusing on oncology and diabetes. The company's strategy of combining its REQORSA gene therapy with approved cancer drugs like Tagrisso and Tecentriq aligns with a broader industry trend towards combination therapies to improve patient outcomes and overcome resistance mechanisms. The formation of a subsidiary for its diabetes program reflects a common strategy in biotech to create focused entities for distinct therapeutic areas, potentially to attract specialized investment or facilitate future partnerships. The challenges in clinical trial enrollment and the need for continuous capital raises are typical for clinical-stage biotech companies, especially those developing novel gene therapies.

Comparison to Industry Standards

• The company's cash runway of only through August 2025 is significantly shorter than typical industry benchmarks for clinical-stage biotech companies, which often aim for 12-18 months of liquidity to avoid distress financing.
• The closure of the Acclaim-2 trial due to enrollment challenges and competition for patients highlights the intense competitive landscape in late-stage NSCLC, where numerous trials involving Keytruda (Merck & Co.) are ongoing, making patient recruitment difficult for smaller players.
• The FDA Fast Track and Orphan Drug Designations for Acclaim-1 and Acclaim-3, respectively, are positive indicators, aligning with industry efforts to accelerate development for serious conditions with unmet needs, similar to designations received by larger pharmaceutical companies for their oncology pipelines.
• The identified material weaknesses in internal controls, particularly regarding segregation of duties and accounting personnel depth, suggest a governance structure that may not yet meet the robust standards expected of more mature public companies in the biotech sector, which typically have more sophisticated financial reporting systems.

Management Changes

Corporate Governance

Legal Proceedings

• No material pending litigation to which the company is a party or to which its property is subject.

Related Party Transactions

• Introgen Research Institute (IRI), formed by the late former CEO Rodney Varner, has an Assignment and Collaboration Agreement with Genprex. No amounts were incurred or due under this agreement at June 30, 2025, or December 31, 2024.

Stakeholder Impact

• Shareholders face significant risk of value erosion due to the going concern warning, Nasdaq delisting threat, and potential for further dilutive capital raises.
• Employees may experience uncertainty regarding job security and company stability given the financial challenges and headcount reductions.
• Clinical trial patients and investigators may face disruptions or cessation of trials, as seen with Acclaim-2, impacting access to potential therapies.
• Creditors and suppliers face increased risk due to the company's limited liquidity and going concern doubts.
• Licensing partners (MD Anderson, University of Pittsburgh, NYU, UTHealth Houston, University of Michigan) may see reduced progress or potential termination of agreements if Genprex cannot secure sufficient funding.

Next Steps

• Complete enrollment of the first 19 patients for interim analysis in the Acclaim-1 Phase 2a expansion portion by the first quarter of 2026.
• Conduct interim analysis for the Acclaim-1 Phase 2a expansion portion in the first half of 2026.
• Complete enrollment of the first 25 patients for interim analysis in the Acclaim-3 Phase 2 expansion portion by the first quarter of 2026.
• Perform a Phase 2 futility analysis for Acclaim-3 after the 25th patient enrolled and treated reaches 18 weeks of follow-up.
• Seek further regulatory guidance from the FDA on IND-enabling studies for the diabetes program (GPX-002) in the second half of 2025.
• Request a hearing before the Nasdaq Hearings Panel to seek an extension for regaining compliance with Nasdaq's listing requirements.
• Consider implementing a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
• Seek stockholder approval at the upcoming 2025 Annual Meeting of Stockholders to issue shares in excess of the Nasdaq Exchange Cap under the 2025 ELOC Facility.
• Continue remediation efforts for identified material weaknesses in internal controls over financial reporting, including implementing new accounting software, review procedures, and potentially hiring additional staff.

Key Dates

Recommendation

The company explicitly states 'substantial doubt as to the Company's ability to continue as a going concern' and has a cash runway only through August 2025. Furthermore, it has received a delisting determination letter from Nasdaq, indicating a high probability of its common stock being delisted. These factors represent severe financial distress and an extremely high risk profile, making the stock unsuitable for investment despite any clinical progress.

Keywords

Gene Therapy, Oncology, Diabetes, REQORSA, NSCLC, SCLC, Clinical Trials, Biotechnology, Nasdaq Delisting, Going Concern, Capital Raise, GPX-002, TUSC2, ONCOPREX Delivery System